Zoetis (ZTS) Liabilities from Discontinued Operations (2015 - 2024)

Zoetis' (ZTS) quarterly Liabilities from Discontinued Operations came in at 26000000.0 in Q3 2024, up 4.0% on a QoQ basis from 25000000.0 in Q2 2024.

Zoetis (ZTS) Liabilities from Discontinued Operations (2015 - 2024) Analysis & Trends

Zoetis (ZTS) has 2 years of Liabilities from Discontinued Operations data on file, last reported at 26000000.0 in Q3 2024.

On a quarterly basis, Liabilities from Discontinued Operations changed N/A year-over-year to 26000000.0 in Q3 2024; TTM through Sep 2024 was 26000000.0, a N/A change from a year earlier, with the FY2015 full-year figure at 4000000.0, changed N/A from the prior year.
Liabilities from Discontinued Operations for Q3 2024 stood at 26000000.0, up from 25000000.0 in the prior quarter.
Over the last five years, Liabilities from Discontinued Operations for ZTS reached as high as 26000000.0 in Q3 2024 and fell as low as 25000000.0 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn
10	Vireo Growth	10.57 Bn	10.41 Bn	59.30 Mn

Download Data